DE69706593D1 - Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier - Google Patents
Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und TierInfo
- Publication number
- DE69706593D1 DE69706593D1 DE69706593T DE69706593T DE69706593D1 DE 69706593 D1 DE69706593 D1 DE 69706593D1 DE 69706593 T DE69706593 T DE 69706593T DE 69706593 T DE69706593 T DE 69706593T DE 69706593 D1 DE69706593 D1 DE 69706593D1
- Authority
- DE
- Germany
- Prior art keywords
- vivo
- vaccine
- virus
- vector
- infected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C17/00—Surface treatment of glass, not in the form of fibres or filaments, by coating
- C03C17/28—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material
- C03C17/30—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material with silicon-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D4/00—Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond ; Coating compositions, based on monomers of macromolecular compounds of groups C09D183/00 - C09D183/16
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Materials Engineering (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Geochemistry & Mineralogy (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9604370A FR2747046B1 (fr) | 1996-04-05 | 1996-04-05 | Nouveaux vaccins issus de plasmovirus |
US09/166,147 US6140114A (en) | 1996-04-05 | 1998-10-05 | Defective viral vaccine particles obtained in vivo or ex vivo |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69706593D1 true DE69706593D1 (de) | 2001-10-18 |
DE69706593T2 DE69706593T2 (de) | 2002-07-11 |
Family
ID=26232637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69706593T Expired - Lifetime DE69706593T2 (de) | 1996-04-05 | 1997-04-07 | Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier |
Country Status (10)
Country | Link |
---|---|
US (1) | US6140114A (de) |
EP (2) | EP1138773A2 (de) |
JP (1) | JP2000508893A (de) |
AT (1) | ATE205537T1 (de) |
AU (1) | AU2394297A (de) |
CA (1) | CA2251027C (de) |
DE (1) | DE69706593T2 (de) |
ES (1) | ES2164309T3 (de) |
FR (1) | FR2747046B1 (de) |
WO (1) | WO1997038118A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ503334A (en) * | 1997-09-15 | 2002-05-31 | Genetic Immunity Llc | A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell |
WO1999019501A1 (en) * | 1997-10-14 | 1999-04-22 | Institute For Vaccine Development | Non-integrating dna vector of retroviral origin having high-protein expression, and secreted immunogenic antigens |
CA2356937A1 (en) * | 1998-12-31 | 2000-07-13 | Richard J. Whitley | Recombinant herpes simplex virus useful for treating neoplastic disease |
US8623379B2 (en) * | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
US20040105871A1 (en) * | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
EP1418940A4 (de) | 2000-03-02 | 2006-09-20 | Univ Emory | Dna expressionsvektoren und verwendungsverfahren |
AU2002218218A1 (en) * | 2000-10-10 | 2002-04-22 | Austrian Nordic Biotherapeutics Ag | A novel system for the evaluation of the activity and/or specificity of a viral component |
EP1201750A1 (de) | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetische Viren und ihre Verwendungen |
AU2002255532A1 (en) * | 2001-02-13 | 2002-10-15 | Joseph D. Mosca | Biological carriers for induction of immune responses |
DE60234018D1 (de) * | 2001-03-08 | 2009-11-26 | Univ Emory | Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene |
EP2055316A1 (de) * | 2003-09-09 | 2009-05-06 | VIRxSYS Corporation | Lentivirale, vektorbasierte Ansätze zur Erzeugung einer Immunantwort auf HIV bei Menschen |
CN100549021C (zh) * | 2004-05-27 | 2009-10-14 | 森托科尔公司 | 猕猴前列腺特异性抗原 |
CA2570563A1 (en) * | 2004-06-15 | 2006-09-28 | Centocor, Inc. | Method for screening agents against human prostate disease |
EP1786445B1 (de) * | 2004-08-25 | 2011-06-08 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Lebendige mikrobielle mikrobizide |
CA2611056C (en) | 2005-06-01 | 2016-06-28 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
KR20140035537A (ko) * | 2006-07-21 | 2014-03-21 | 캘리포니아 인스티튜트 오브 테크놀로지 | 수지상 세포 백신접종을 위한 표적화된 유전자의 전달 |
US20090169519A1 (en) * | 2007-02-21 | 2009-07-02 | Rajesh Shah | Medicinal formulation containing a combination of hiv type i and hiv type ii |
RS53257B2 (sr) | 2009-07-24 | 2018-06-29 | Immune Design Corp | Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa |
EP3187585A1 (de) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
DK2831095T3 (en) | 2012-03-30 | 2019-02-18 | Immune Design Corp | LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN |
US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
CN109843321A (zh) | 2016-06-22 | 2019-06-04 | 国际艾滋病疫苗行动组织公司 | 作为结核病疫苗的重组巨细胞病毒载体 |
EP3697806A4 (de) | 2017-10-17 | 2021-10-27 | International AIDS Vaccine Initiative, Inc. | Tuberkulose-antigen-kassetten |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2066053C (en) * | 1989-08-18 | 2001-12-11 | Harry E. Gruber | Recombinant retroviruses delivering vector constructs to target cells |
US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
DE69332519T2 (de) * | 1992-02-28 | 2003-07-17 | Syngenix Ltd., Heydon | Defekte verpackende nicht-oncoviren vektoren aus mpmv |
CA2117884A1 (en) * | 1992-03-27 | 1993-10-14 | Anna Aldovini | Non-infectious hiv particles and uses therefor |
DE69430646T2 (de) * | 1993-02-17 | 2003-01-02 | Wisconsin Alumni Research Foundation, Madison | Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen |
FR2716459B1 (fr) * | 1994-02-22 | 1996-05-10 | Univ Paris Curie | Système hôte-vecteur utilisable en thérapie génique. |
WO1995026411A2 (en) * | 1994-03-25 | 1995-10-05 | The Uab Research Foundation | Composition and methods for creating syngeneic recombinant virus-producing cells |
FR2722208B1 (fr) * | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
AT402898B (de) * | 1994-08-08 | 1997-09-25 | Int Centre Genetic Eng & Bio | Molekulares präsentiersystem |
US6080408A (en) * | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
AU716219B2 (en) * | 1995-02-24 | 2000-02-24 | Clipmate Corp. | Electric detonator and lead connector assembly |
-
1996
- 1996-04-05 FR FR9604370A patent/FR2747046B1/fr not_active Expired - Fee Related
-
1997
- 1997-04-07 CA CA002251027A patent/CA2251027C/fr not_active Expired - Lifetime
- 1997-04-07 EP EP01102630A patent/EP1138773A2/de not_active Withdrawn
- 1997-04-07 AU AU23942/97A patent/AU2394297A/en not_active Abandoned
- 1997-04-07 ES ES97400796T patent/ES2164309T3/es not_active Expired - Lifetime
- 1997-04-07 JP JP9535922A patent/JP2000508893A/ja active Pending
- 1997-04-07 DE DE69706593T patent/DE69706593T2/de not_active Expired - Lifetime
- 1997-04-07 EP EP97400796A patent/EP0799893B1/de not_active Expired - Lifetime
- 1997-04-07 AT AT97400796T patent/ATE205537T1/de not_active IP Right Cessation
- 1997-04-07 WO PCT/FR1997/000619 patent/WO1997038118A1/fr active Search and Examination
-
1998
- 1998-10-05 US US09/166,147 patent/US6140114A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69706593T2 (de) | 2002-07-11 |
CA2251027A1 (fr) | 1997-10-16 |
EP0799893B1 (de) | 2001-09-12 |
JP2000508893A (ja) | 2000-07-18 |
AU2394297A (en) | 1997-10-29 |
EP0799893A1 (de) | 1997-10-08 |
FR2747046A1 (fr) | 1997-10-10 |
FR2747046B1 (fr) | 1998-06-19 |
WO1997038118A1 (fr) | 1997-10-16 |
CA2251027C (fr) | 2009-11-10 |
US6140114A (en) | 2000-10-31 |
ATE205537T1 (de) | 2001-09-15 |
ES2164309T3 (es) | 2002-02-16 |
EP1138773A2 (de) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69706593D1 (de) | Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier | |
DK0742834T4 (da) | Fremgangsmåde til fremstilling af en virusvektor på mindst 20 kb ved intermolekylær homolog rekombination i en prokaryot celle | |
EP1683858A3 (de) | Virale Zubereitungen, Vektoren, Immunogene und Impfstoffe | |
WO1995006743A3 (en) | Methods and compositions for the large scale production of recombinant adeno-associated virus | |
CA2596274A1 (en) | Recombinant mva virus, and the use thereof | |
AU1138388A (en) | Hybrid rna virus | |
ATE419368T1 (de) | System zum transfer und zur expression von heterologen genen ins knochenmark in vivo | |
EP1923467A3 (de) | Adenovirusvektoren für die Gentherapie | |
ATE188740T1 (de) | Viruspartikel mit veraendertem wirtspektrum | |
CY1106513T1 (el) | Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna | |
DE69535018D1 (de) | Papillomavirus vakzine | |
NZ234586A (en) | Peptide of a t-cell receptor capable of inducing protection from immune-related disease | |
NZ503039A (en) | Recombinant porcine adenovirus vector | |
NZ503830A (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
CA2321964A1 (en) | Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus | |
DK0632129T3 (da) | Rekombinante foamy-virusvektorer til medicinsk og diagnostisk anvendelse, og fremgangsmåder til at præparere rekombinante foamy-virusvektorer | |
AU784884B2 (en) | Methods for introducing genes into mammalian subjects | |
ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
EP2145961A3 (de) | Adenovirus-Typ-3-Genom des Schweins | |
NZ226904A (en) | Hiv-2 env protein polypeptides and their preparation and use | |
WO1994013812A3 (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
CN109135737A (zh) | 一种氮掺杂碳量子点及其制备方法和应用 | |
HK1002284A1 (en) | Novel implant and novel vector for the treatment of acquired diseases | |
ATE237629T1 (de) | Rekombinanter virus der marek-krankheit, verfahren zur herstellung dieses viruses und diesen enthaltender impfstoff | |
AP2005A (en) | Process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |